Analyses of tumour samples from the ideal 1 and 2 trials (n = 425) evaluating gefitinib monotherapy demonstrated that patients whose tumour had an EGFR mutation had a better or with gefitinib than did patients lacking the mutation (n = 79: 46% vs.10%, p = 0.005)80. Here, EGFR is linked to neoplasm.